KANSAS CITY, Kan., Dec. 28, 2017 /PRNewswire/ -- Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced that Cingulate's Chairman and Chief Executive Officer, Shane J Schaffer, will present at the 10th Annual Biotech Showcase™ on Tuesday, January 9, 2018, at 2:15 p.m. Pacific Time. The conference takes place January 8–10, 2018, at the Hilton San Francisco Union Square, San Francisco, California.
Management will discuss the regulatory strategy for the Company's lead product candidates CTX-1301 and CTX-1302 as well as the innate value of the drug delivery platform technology that enabled the creation of these two potential blockbusters. In addition to the scheduled presentation, management will be available for 1:1 meetings. For more information about the conference or to schedule a meeting, please contact Jonathon D. Brzezinski, Ph.D. at email@example.com.
About Cingulate Therapeutics
Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing the Company's innovative drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two proprietary, first-line stimulant medications, CTX-1301 (dexmethylphenidate) and CTX-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTX-1301 and CTX-1302 utilize an innovative, flexible core tableting technology with a Target Product Profile designed to deliver a rapid onset and last the entire active day while minimizing the afternoon crash and impact on sleep and appetite. The Company has completed a Proof of Concept Phase I clinical trial and plans to implement the full clinical plan for both CTX-1301 and CTX-1302 in early 2018. Cingulate anticipates filing INDs for both products in the first quarter of 2018 and will pursue approval via the accelerated 505(b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information visit www.cingulatetherapeutics.com.
For Investors & Media:
SOURCE Cingulate Therapeutics, LLC